Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment

Tumor‐derived cell lines play an important role in the investigation of tumor biology and genetics. Across a wide array of studies, they have been tools of choice for the discovery of important genes involved in cancer and for the analysis of the cellular pathways that are impaired by diverse oncogenic events. They are also invaluable for screening novel anticancer drugs. The TP53 protein is a major component of multiple pathways that regulate cellular response to various types of stress. Therefore, TP53 status affects the phenotype of tumor cell lines profoundly and must be carefully ascertained for any experimental project. In the present review, we use the 2014 release of the UMD TP53 database to show that TP53 status is still controversial for numerous cell lines, including some widely used lines from the NCI‐60 panel. Our analysis clearly confirms that, despite numerous warnings, the misidentification of cell lines is still present as a silent and neglected issue, and that extreme care must be taken when determining the status of p53, because errors may lead to disastrous experimental interpretations. A novel compendium gathering the TP53 status of 2,500 cell lines has been made available (http://p53.fr). A stand‐alone application can be used to browse the database and extract pertinent information on cell lines and associated TP53 mutations. It will be updated regularly to minimize any scientific issues associated with the use of misidentified cell lines (http://p53.fr).

[1]  P. Taschner,et al.  Recommendations for Analyzing and Reporting TP53 Gene Variants in the High‐Throughput Sequencing Era , 2014, Human mutation.

[2]  Mathias Wilhelm,et al.  Global proteome analysis of the NCI-60 cell line panel. , 2013, Cell reports.

[3]  P. Meltzer,et al.  The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. , 2013, Cancer research.

[4]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[5]  G. Wahl,et al.  MDM2, MDMX and p53 in oncogenesis and cancer therapy , 2013, Nature Reviews Cancer.

[6]  D. Lane,et al.  Detecting p53 isoforms at protein level. , 2013, Methods in molecular biology.

[7]  D. Lane,et al.  Detecting and quantifying p53 isoforms at mRNA level in cell lines and tissues. , 2013, Methods in molecular biology.

[8]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[9]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[10]  T. Soussi.  Advances in carcinogenesis: a historical perspective from observational studies to tumor genome sequencing and TP53 mutation spectrum analysis. , 2011, Biochimica et biophysica acta.

[11]  M. Morita,et al.  Copy-Neutral Loss of Heterozygosity at the p53 Locus in Carcinogenesis of Esophageal Squamous Cell Carcinomas Associated with p53 Mutations , 2011, Clinical Cancer Research.

[12]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[13]  Luc Girard,et al.  Lung cancer cell lines as tools for biomedical discovery and research. , 2010, Journal of the National Cancer Institute.

[14]  P. Deloukas,et al.  Signatures of mutation and selection in the cancer genome , 2010, Nature.

[15]  E. Birney,et al.  A small cell lung cancer genome reports complex tobacco exposure signatures , 2009, Nature.

[16]  American Type Culture Collection Standards Development Orga ASN-0002.  Cell line misidentification: the beginning of the end , 2010, Nature Reviews Cancer.

[17]  A. Hollestelle,et al.  Comment Re: MDA-MB-435 and M14 cell lines: identical but not M14 Melanoma? , 2009, Cancer research.

[18]  A. Chambers,et al.  MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? , 2009, Cancer research.

[19]  Thierry Soussi,et al.  Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination , 2008, Cancer biology & therapy.

[20]  Jan Österreicher,et al.  Gamma irradiation of human leukaemic cells HL-60 and MOLT-4 induces decrease in Mcl-1 and Bid, release of cytochrome c, and activation of caspase-8 and caspase-9 , 2008, International journal of radiation biology.

[21]  Ulrich Lehmann,et al.  MDA-MB-435: The questionable use of a melanoma cell line as a model for human breast cancer is ongoing , 2007, Cancer biology & therapy.

[22]  R. Ozols,et al.  RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model , 2007, Clinical Cancer Research.

[23]  Dana Ravid,et al.  A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. , 2007, Cancer letters.

[24]  Chad J. Creighton,et al.  MDA-MB-435 cells are derived from M14 Melanoma cells––a loss for breast cancer, but a boon for melanoma research , 2007, Breast Cancer Research and Treatment.

[25]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[26]  Richard Lugg,et al.  Mutation analysis of 24 known cancer genes in the NCI-60 cell line set , 2006, Molecular Cancer Therapeutics.

[27]  R. Shoemaker.  The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[28]  B. Strauss,et al.  The DU145 human prostate carcinoma cell line harbors a temperature‐sensitive allele of p53 , 2006, The Prostate.

[29]  D. Grochová,et al.  Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124. , 2005, Oncology reports.

[30]  David P Lane,et al.  p53 isoforms can regulate p53 transcriptional activity. , 2005, Genes & development.

[31]  K. Tsuneyama,et al.  Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines. , 2005, Pathology, research and practice.

[32]  T. Carey,et al.  Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region , 2002, Head & neck.

[33]  H. Drexler,et al.  Persistent use of misidentified cell lines and its prevention , 2002, Genes, chromosomes & cancer.

[34]  Y. Matsuo,et al.  p53 alterations in human leukemia–lymphoma cell lines: in vitroartifact or prerequisite for cell immortalization? , 2000, Leukemia.

[35]  I. Wistuba,et al.  Comparison of molecular changes in cervical intraepithelial neoplasia in HIV-positive and HIV-indeterminate subjects. , 1999, Gynecologic oncology.

[36]  A. Kropveld,et al.  Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[37]  D. Scudiero,et al.  Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. , 1998, Journal of the National Cancer Institute.

[38]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[39]  S. Parodi,et al.  p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. , 1997, Cancer research.

[40]  G. Thomas,et al.  Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines. , 1996, Oncogene.

[41]  H. Abe,et al.  Clonality and stability of the p53 gene in human astrocytic tumor cells: Quantitative analysis of p53 gene mutations by yeast functional assay , 1996, International journal of cancer.

[42]  M. Imamura,et al.  K‐ras and p53 Alterations in Genomic DNA and Transcripts of Human Pancreatic Adenocarcinoma Cell Lines , 1994, Japanese journal of cancer research : Gann.

[43]  V. Chow,et al.  Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line. , 1993, Cancer letters.

[44]  W. Isaacs,et al.  Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. , 1991, Cancer research.

[45]  W. Bodmer,et al.  p53 mutations in colorectal cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[46]  W. Nelson-Rees,et al.  Cross-contamination of cells in culture. , 1981, Science.

[47]  R. Dulbecco,et al.  PLAQUE FORMATION AND ISOLATION OF PURE LINES WITH POLIOMYELITIS VIRUSES , 1954, The Journal of experimental medicine.